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Formulation development for T-cells is challenging due to various considerations including optimization of the 
hold times during filling and after thawing for CAR T-cell administration.  Optimization of the formulation of a 
cryopreservation medium for CAR T-cells was determined through small and large scale formulation screens 
utilizing a model T-cell line.  Pan T-cells were formulated in various combinations of harvest medium and 
cryopreservation medium to evaluate if any offered superior cell viability and viable cell density (VCD) following 
thaw when compared to the platform formulation containing HSA and high DMSO.  Viability and VCD were 
measured immediately after thaw and up to 3 days post reconstitution to determine any effect of the 
cryopreservation media on the cell recovery. Initial screens showed that a difference between cryopreservation 
media could be observed and larger formulation robustness studies confirmed this difference. Taken together, 
the results of these studies confirm the development of a robust cryopreservation medium for T-cell formulation. 
 
